Please provide your email address to receive an email when new articles are posted on . The novel gene therapy is aimed at optogenetic vision restoration in diseases causing blindness. The Series A ...

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related ...

Please provide your email address to receive an email when new articles are posted on . The trial, which included 27 participants, met its safety and efficacy endpoints at 52 weeks and 76 weeks. The ...